Clinical trials: Sitagliptin
Healhty
Bioequivalence of Sitagliptin/Metformin Tablets in Healthy Chinese Adults Under Fasting and Fed Conditions
This study evaluated whether a test formulation of sitagliptin/metformin tablets (manufactured by Jiangxi Shimei Pharmaceutical Co., Ltd.) is bioequivalent to the reference product Janumet (sitagliptin phosphate/metformin…
- Trial name
- NCT07910682
- Testing
- Sitagliptin/metformin hydrochloride tablets (50 mg/850 mg), Sitagliptin/metformin hydrochloride reference tablets (50 mg/850 mg)
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Guangzhou Panyu Central Hospital
Hyperlipidemia
Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans
Recent studies in both animals and humans has demonstrated that the hormone GLP-1 (glucagon like peptide 1) reduces intestinal production of lipoprotein particles.
- Trial name
- NCT01600703
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Healthy Volunteers
Bioequivalence Study of Sitagliptin/Metformin Extended-Release Tablets in Healthy Subjects
The main purpose of this study is to compare the pharmacokinetics (how the body absorbs and clears the drug) and evaluate the bioequivalence of two formulations of sitagliptin/metformin hydrochloride extended-release tablets (50…
- Trial name
- NCT07679711
- Testing
- Sitagliptin / Metformin hydrochloride extended-release tablet (Test), Sitagliptin / Metformin hydrochloride extended-release tablet (Reference)
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Type 2 Diabetes
Cognitive Protective Effect of Newer Antidiabetic Drugs
The proposed study aims to: 1. Explore the cognitive protective effects of SGLT2 inhibitors and DPP-4 inhibitors in patients attending diabetic clinics in Alexandria 2.
- Trial name
- NCT05347459
- Testing
- Dapagliflozin, Empagliflozin, Canagliflozin
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Alexandria University
Bioequivalence, Type 2 Diabetes
Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers
The objective of this study was to determine the bioequivalence of two different formulations of sitagliptin/ metformin after a single oral dose administration under fed conditions.
- Trial name
- NCT05549583
- Testing
- Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Hypertension, Diabetes Type 2
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme…
- Trial name
- NCT01413542
- Testing
- Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.
- Trial name
- NCT05900531
- Testing
- K-757, K-757 and open-label sitagliptin, K-757 and K-833
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TriGemX Bio, Inc.
Obesity
Incretin Effect in People With Impaired Fasting Glucose
Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to abnormal EGP and insulin secretion in people…
- Trial name
- 1651 (NCT00795275)
- Testing
- Sitagliptin Phosphate
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379
This is a randomized, open-label, single dose, crossover, phase Ⅰ trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-379 in healthy volunteers
- Trial name
- NCT06204107
- Testing
- CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Obesity
A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
The purposes of this study are to: Find out how much of the study drugs are in the blood of healthy subjects after taking multiple doses of VI-0521, metformin and sitagliptan.
- Trial name
- NCT00842400
- Testing
- Metformin, VI-0521, Sitagliptan, Probenecid
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Diabetes Mellitus
Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin
The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of sitagliptin in healthy volunteers.
- Trial name
- NCT00960453
- Testing
- Sitagliptin
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Type 2 Diabetes Mellitus
Changes in Bone Turnover With Increased Incretin Hormone Exposure
The purpose of this study is to determine if the use of sitagliptin increases bone formation and reduces bone turnover in postmenopausal women with type 2 diabetes.
- Trial name
- DRTC (NCT01374568)
- Testing
- sitagliptin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Type 2 Diabetes
A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)
This study will determine the effect of concomitant administration of sitagliptin and metformin on post-meal incretin hormone concentrations in healthy adults.
- Trial name
- NCT00975052
- Testing
- sitagliptin phosphate, Comparator: metformin, Comparator: sitagliptin and metformin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects
Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects
An open-label, randomized, single-dose, two-period, two-group, crossover study was conducted in 48 healthy Chinese volunteers under fasted or fed conditions (24 volunteers for each condition) to assess the bioequivalence between…
- Trial name
- NCT04877106
- Testing
- Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg), Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Type 2 Diabetes Mellitus, PreDiabetes
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of DPPIV inhibitor in T2DM patients with different…
- Trial name
- GLP-1 (NCT03659461)
- Testing
- Sitagliptin
- Where
- Malaysia
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
Patients with diabetes have high blood sugar levels (hyperglycemia) because pancreatic beta-cells no longer produce sufficient insulin.
- Trial name
- NCT00813228
- Testing
- Sitagliptin (Januvia)
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Bioequivalance
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-IC004 (NCT07763951)
- Testing
- Janumet XR, Sitagliptin/Metformin FDC
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Type 2 Diabetes
SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1 receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal systems in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01744236
- Testing
- Liraglutide, Sitagliptin, Exenatide
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Healthy
DPP4 Inhibition & Beta Cell Function
This study is being done to determine the role of a hormone, glucagon-like peptide 1 (GLP-1), on insulin secretion and to study how GLP-1 works in in diabetic individuals as compared to non-diabetic individuals, under fasting…
- Trial name
- NCT02683187
- Testing
- Active Comparator: Sitagliptin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- David D'Alessio, M.D.
Healthy Subjects
A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6012 and each component in healthy adult volunteers.
- Trial name
- NCT05403281
- Testing
- DW6012
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.